Solentim reports continued strong growth in 2019
NEWS – Bournemouth, UK – 8th August 2019: Solentim, the innovator and World leader in Cell Line Development instrumentation, is pleased to announce that it achieved very strong revenue growth and financial results for the first half of 2019.
Commenting on the performance, Dr Ian Taylor, Chief Commercial Officer noted “Our results are in line with the current surge in the bioprocessing sector observed by analysts and results recently reported from industry leaders such as Sartorius.” He went on to add, “Our growth has been driven by strong uptake and adoption by new customers of our VIPS single cell cloning system with its unique ability to both isolate single cells and perform with whole well imaging. Additionally, we have experienced synergies through our partnerships with ATUM and SAL Scientific which have engaged us with new customers.”
Solentim recently celebrated 9 years in business and plans to maintain its focus on cell line development for the long-term. Dr Taylor finished by saying that “Solentim now has a customer base of around 300 customers worldwide for our products. We continue to drive forward, and new products are planned for introduction next year through continuous re-investments by the company and our grant funded project with ValitaCell.”